Genome technologies in pulmonology: a role of microRNA in asthma and COPD development

MicroRNAs (miRNAs) are small noncoding RNA molecules that affect gene expression and thus take part in the epigenetic regulation of almost all physiological and pathological processes. About 1,800 human miRNAs have been discovered to date; however, biological functions and protein targets for the majority remain to be unknown. Within the respiratory system, miRNAs contribute to the lung growth and lifelong maintenance of pulmonary homeostasis. Recently, the leading role of miRNAs in pathogenesis of various pulmonary diseases has been found, including asthma, chronic obstructive pulmonary disease (COPD) and lung cancer. Due to a significant progress in studying interactions between genes and their products and environmental factors, a great role of epigenetic variability, which is gene expression change not related to DNA damage, but could be inherited consistently, became apparent. There are three levels of epigenetic regulation corresponding to three main mechanisms: genomic (DNA methylation), proteomic (histone modification) and transcriptomic (regulation through RNA, primarily miRNA). Extending our knowledge on a role of miRNAs for the respiratory system could open new therapeutic targets and diagnostic markers for respiratory diseases, particularly asthma and COPD.

1. Durham A.L., Adcock I.M. Basic science: Epigenetic programming and the respiratory system. Breathe. 2013; 9 (4): 279–288.

2. Gorbunova V.N., Pchelina S.N., Shvartsman A.L. Introduction into molecular medicine: A study guide. Saint-Petersburg, Izdatel'stvo Politekhnicheskogo universiteta; 2011: 214 (in Russian).

3. Pinney S.E. Mammalian Non-CpG Methylation: Stem Cells and Beyond. Biology (Basel). 2014; 3 (4): 739–751.

4. Tsicopoulos A., de Nadai P., Glineur C. Environmental and genetic contribution in airway epithelial barrier in asthma pathogenesis. Curr. Opin. Allergy Clin. Immunol. 2013; 13 (5): 495–499.

5. Barnes P.J., Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2013; 131 (3): 636–645.

6. Lu T.X., Rothenberg M.E. Diagnostic, functional, and therapeutic roles of microRNA in allergic diseases. J. Allergy Clin. Immunol. 2013; 132 (1): 3–13.

7. Chen Y., Verfaillie C.M. MicroRNAs: the fine modulators of liver development and function. Liver Int. 2014; 34 (7): 976–990.

8. Hata A., Kang H. Functions of the bone morphogenetic protein signaling pathway through microRNAs (review). Int. J. Mol. Med. 2015; 35 (3): 563–568.

9. Oglesby I.K., McElvaney N.G., Greene C.M. MicroRNAs in inflammatory lung disease-master regulators or target practice? Respir. Res. 2010; 11: 148.

10. Rupani H., Sanchez-Elsner T., Howarth P. MicroRNAs and respiratory diseases. Eur. Respir. J. 2013; 41 (3): 695–705.

11. Pritchard C.C., Cheng H.H., Tewari M. MicroRNA profiling: approaches and considerations. Nat. Rev. Genet. 2012; 13 (5): 358–369.

12. Kochetov A.G., Zhirov I.V., Masenko V.P. et al. Perspectives of microRNA use for diagnosis and therapy of heart failure. Kardiologicheskiy vestnik. 2014; 10 (2): 62–67 (in Russian).

13. Sinha A., Yadav A.K., Chakraborty S. et al. Exosome-enclosed microRNAs in exhaled breath hold potential for biomarker discovery in patients with pulmonary diseases. J. Allergy Clin. Immunol. 2013; 132 (1): 219–222.

14. Sessa R., Hata A. Role of microRNAs in lung development and pulmonary diseases. Pulm. Circ. 2013; 3 (2): 315–328.